SI-BONE (SIBN) Set to Announce Quarterly Earnings on Tuesday

SI-BONE (NASDAQ:SIBN) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

SI-BONE Stock Down 1.6 %

SI-BONE stock opened at $15.32 on Friday. The firm has a market capitalization of $638.69 million, a PE ratio of -15.17 and a beta of 1.22. The company’s 50-day moving average is $14.22 and its 200-day moving average is $14.31. SI-BONE has a fifty-two week low of $11.76 and a fifty-two week high of $21.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.17 and a quick ratio of 8.12.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 9,967 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $13.84, for a total value of $137,943.28. Following the completion of the sale, the chief executive officer now directly owns 492,923 shares in the company, valued at approximately $6,822,054.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other SI-BONE news, insider Anthony J. Recupero sold 2,087 shares of SI-BONE stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $14.17, for a total value of $29,572.79. Following the sale, the insider now owns 236,717 shares of the company’s stock, valued at approximately $3,354,279.89. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Laura Francis sold 9,967 shares of SI-BONE stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the transaction, the chief executive officer now owns 492,923 shares of the company’s stock, valued at $6,822,054.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,017 shares of company stock worth $349,587. 3.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SIBN has been the topic of a number of analyst reports. Truist Financial decreased their target price on shares of SI-BONE from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. Needham & Company LLC dropped their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Morgan Stanley dropped their price target on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE currently has a consensus rating of “Buy” and a consensus price target of $22.67.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.